Rakovina Therapeutics Inc.
Michelle Seltenrich is an accomplished professional with extensive experience in corporate development and operations within the biopharmaceutical sector. Currently serving as Director of Corporate Development at Rakovina Therapeutics, Michelle focuses on enhancing awareness of the company's pipeline and technology. Previous roles include Director of FP&A at Zymeworks Inc. and Vice President of Operations at Sirona Biochem Corp., where Michelle was instrumental in negotiating significant licensing deals. Expertise spans from managing operational processes and budgets to overseeing corporate development efforts at Forbes Medi-Tech Inc. and establishing laboratory management at the University of British Columbia. Michelle holds a Master's degree in Business Administration and a Graduate Diploma in Business Administration from Simon Fraser University, as well as a Bachelor of Science in Biology from The University of British Columbia.
This person is not in the org chart
This person is not in any teams
Rakovina Therapeutics Inc.
Rakovina Therapeutics’ focus is the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics fromHealth Canada, the United States Food and Drug Administration and similar international regulatory agencies